The Clinical Research Service (CRS) was established in December, 1986 as a shared resource to facilitate development, implementation, and completion of all UPCI clinical research studies. A part of the global UPCI infrastructure for clinical trial support, the CRS works in tandem with the Protocol Review Committees (PRC) and the Data Safety and Monitoring Committee (DSMC); all three entities function under the oversight of the Clinical Research Oversight Committee (CROC). Adam Brufsky, M.D., Ph.D., Associate Director for Clinical Investigation oversees the CRS. Steve Mulcahy, MS serves as Director, CRS while Holly Goe, BSN, serves as Associate Director, CRS. The CRS serves as the coordinating center for oversight, management, and monitoring for all UPCI clinical research activities. It provides assistance with study development and implementation, IRB submission and processing of PRC-approved trials, patient recruitment, study coordination, and specimen and data collection for all investigators conducting cancer-related studies at the University of Pittsburgh and UPMC Cancer Centers. The CRS database Clinical Trials Management Application (CTMA) maintains up to date documentation on the status of each study and facilitates timely submission of all required documents and amendments to the IRB, study renewal forms, progress reports. Data Safety Monitoring information, Serious Adverse Events, monthly reports, IRB and other correspondence. The CRS has continued to grow and adapt to the scientific, regulatory and financial challenges of cancer clinical research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA047904-24
Application #
8382694
Study Section
Special Emphasis Panel (ZCA1-RTRB-L)
Project Start
Project End
Budget Start
2012-08-01
Budget End
2013-07-31
Support Year
24
Fiscal Year
2012
Total Cost
$387,666
Indirect Cost
$78,573
Name
University of Pittsburgh
Department
Type
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Du, Tian; Sikora, Matthew J; Levine, Kevin M et al. (2018) Key regulators of lipid metabolism drive endocrine resistance in invasive lobular breast cancer. Breast Cancer Res 20:106
Wang, Zehua; Yang, Bo; Zhang, Min et al. (2018) lncRNA Epigenetic Landscape Analysis Identifies EPIC1 as an Oncogenic lncRNA that Interacts with MYC and Promotes Cell-Cycle Progression in Cancer. Cancer Cell 33:706-720.e9
Volonte, Daniela; Vyas, Avani R; Chen, Chen et al. (2018) Caveolin-1 promotes the tumor suppressor properties of oncogene-induced cellular senescence. J Biol Chem 293:1794-1809
Ma, Jing; Salamoun, Joseph; Wipf, Peter et al. (2018) Combination of a thioxodihydroquinazolinone with cisplatin eliminates ovarian cancer stem cell-like cells (CSC-LCs) and shows preclinical potential. Oncotarget 9:6042-6054
Linden, Hannah M; Peterson, Lanell M; Fowler, Amy M (2018) Clinical Potential of Estrogen and Progesterone Receptor Imaging. PET Clin 13:415-422
Liu, Zhuqing; McMichael, Elizabeth L; Shayan, Gulidanna et al. (2018) Novel Effector Phenotype of Tim-3+ Regulatory T Cells Leads to Enhanced Suppressive Function in Head and Neck Cancer Patients. Clin Cancer Res 24:4529-4538
Song, Xinxin; Zhu, Shan; Xie, Yangchun et al. (2018) JTC801 Induces pH-dependent Death Specifically in Cancer Cells and Slows Growth of Tumors in Mice. Gastroenterology 154:1480-1493
Santos, Patricia M; Butterfield, Lisa H (2018) Dendritic Cell-Based Cancer Vaccines. J Immunol 200:443-449
Krivinko, Josh M; Erickson, Susan L; Ding, Ying et al. (2018) Synaptic Proteome Compensation and Resilience to Psychosis in Alzheimer's Disease. Am J Psychiatry 175:999-1009
Chartoumpekis, Dionysios V; Yagishita, Yoko; Fazzari, Marco et al. (2018) Nrf2 prevents Notch-induced insulin resistance and tumorigenesis in mice. JCI Insight 3:

Showing the most recent 10 out of 1187 publications